Roswell Park Comprehensive Cancer Center, Buffalo, NY
Shipra Gandhi , Karla V. Ballman , Michelle D. Holmes , Kala Visvanathan , Banu Symington , Margaret Carvan , Carol Matyka , Anna Weiss , Eric P. Winer , Wajeeha Razaq , Lisa A. Carey , Ann H. Partridge , Wendy Y. Chen
Background: A011502 is a phase 3 randomized double-blind clinical trial that enrolled high-risk nonmetastatic breast cancer (BC) patients (pts) and randomized pts to aspirin 300 mg daily vs. placebo. There was no significant difference in invasive disease-free survival (iDFS) between the two arms. A secondary objective was to determine the association of inflammation-affiliated factors (stress, depression, poor sleep quality and pain) with iDFS and overall survival (OS). We hypothesized that these baseline factors are associated with worse clinical outcomes. Methods: At baseline, 2735, 2720, 2422 and 2610 pts completed Perceived Stress Scale (PSS), Brief Pain Inventory (BPI), Pittsburgh Sleep Quality Index (PSQI) and Center for Epidemiologic Studies Depression Scale Revised (CESD-R) respectively. Stress was categorized with PSS scores: low (0-13), moderate (14-26) or high stress (27-40). Pain was categorized with BPI scores: none/mild (0-3) or moderate/severe (≥4). Sleep quality was categorized with PSQI scores: good (0-5) or poor ( > 5).Depression was categorized with CESD-R scores: no depression (0-15) or depression (≥16). Associations between the measures of interest and outcomes were performed with multivariable Cox models controlling for age, body mass index, time since diagnosis, race, ethnicity, hormone receptor status and treatment arm. Results: Median follow up was 35 months. The associations from multivariable Cox model are shown in Table 1. Pts who reported high PSS had significantly worse iDFS and (non-significant) worse OS. Moderate/severe average (avg) pain was significantly associated with worse iDFS and OS. Poor sleep quality and depression were associated with worse iDFS and OS but not statistically significant. Conclusions: Pts reporting higher stress and pain at baseline had worse outcomes. We acknowledge that both pain and stress may be related to other non-cancer issues (chronic comorbidities). Our study highlights the need for clinical trials to consider including questionnaires to assess pt-reported outcomes. Future studies are warranted to determine if measures to decrease pain and stress would improve BC outcomes. U10CA180821, U10CA180882, UG1CA233196; https://acknowledgments.alliancefound.org. NCT02927249: Clinical trial information: NCT02927249.
iDFS | OS | ||||||
---|---|---|---|---|---|---|---|
Measurement | Events | HR (95% CI) | p | Events | HR (95% CI) | p | |
PSS | Low n = 1617 | 144 | 1.00 (ref) | 0.04 | 62 | 1.00 (ref) | 0.07 |
Moderate n = 1051 | 85 | 0.96 (0.73, 1.26) | 40 | 1.04 (0.69, 1.56) | |||
High n = 64 | 11 | 2.13 (1.14, 3.96) | 6 | 2.55 (1.09, 5.93) | |||
Avg BPI | No/mild n = 2254 | 182 | 1.00 (ref) | < 0.01 | 75 | 1.00 (ref) | < 0.01 |
Mod/severe n = 464 | 59 | 1.57 (1.16, 2.14) | 33 | 2.09 (1.36, 3.19) | |||
PSQI | Good n = 804 | 57 | 1.00 (ref) | 0.11 | 22 | 1.00 (ref) | 0.10 |
Poor n = 1615 | 147 | 1.29 (0.95, 1.75) | 70 | 1.50 (0.92, 2.43) | |||
CESD-R | Not depressed n = 2230 | 193 | 1.00 (ref) | 0.14 | 87 | 1.00 (ref) | 0.42 |
Depressed n = 377 | 41 | 1.29 (0.92, 1.82) | 19 | 1.23 (0.74, 2.03) |
HR: Hazard Ratio; CI: Confidence Interval.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Lanxin Zhang
ASCO Plenary Series
First Author: Wendy Y. Chen
2023 ASCO Annual Meeting
First Author: Shipra Gandhi
2023 ASCO Annual Meeting
First Author: Michael Untch